Bicycle Therapeutics (NASDAQ:BCYC) Trading Down 3.9% – What’s Next?

Bicycle Therapeutics plc (NASDAQ:BCYC) fell 3.9% during mid-day trading on Thursday . The stock traded as low as $13.98 and last traded at $13.98. 12,438 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 352,924 shares. The stock had previously closed at $14.55.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. JMP Securities reduced their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research report on Wednesday, December 18th. B. Riley reduced their price target on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a report on Friday, December 13th. HC Wainwright reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Bicycle Therapeutics in a report on Monday, January 13th. Stephens began coverage on shares of Bicycle Therapeutics in a research report on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price objective on the stock. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $35.00 target price on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $34.50.

Bicycle Therapeutics Trading Down 1.8 %

The stock has a market cap of $921.13 million, a P/E ratio of -4.05 and a beta of 0.92. The stock’s 50-day moving average is $17.54 and its 200-day moving average is $21.46.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business had revenue of $2.68 million during the quarter, compared to analysts’ expectations of $6.82 million. During the same period last year, the firm posted ($1.26) earnings per share. The business’s revenue was down 50.0% on a year-over-year basis. On average, equities analysts forecast that Bicycle Therapeutics plc will post -3.05 EPS for the current year.

Insider Buying and Selling at Bicycle Therapeutics

In other news, CAO Travis Alvin Thompson sold 6,256 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $25.11, for a total transaction of $157,088.16. Following the completion of the transaction, the chief accounting officer now owns 19,241 shares in the company, valued at approximately $483,141.51. This trade represents a 24.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Santiago Arroyo sold 4,943 shares of Bicycle Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $69,646.87. Following the completion of the transaction, the insider now directly owns 69,057 shares in the company, valued at $973,013.13. This represents a 6.68 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 33,933 shares of company stock valued at $549,501. 8.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BCYC. Assetmark Inc. acquired a new position in shares of Bicycle Therapeutics in the 3rd quarter worth $34,000. GAMMA Investing LLC increased its stake in Bicycle Therapeutics by 105.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after purchasing an additional 1,038 shares in the last quarter. Avior Wealth Management LLC purchased a new position in Bicycle Therapeutics in the 4th quarter worth about $57,000. China Universal Asset Management Co. Ltd. raised its holdings in Bicycle Therapeutics by 69.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock worth $162,000 after buying an additional 2,918 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in Bicycle Therapeutics by 26.8% during the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after buying an additional 1,782 shares in the last quarter. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.